We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brain Imaging: Cocaine Effects & Medication Development - 5

This study has been withdrawn prior to enrollment.
(Study never opened; never enrolled participants)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000270
First Posted: September 21, 1999
Last Update Posted: August 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
New York State Psychiatric Institute
  Purpose
The purpose of this study is to define temporal profile of brain activation (rCBF) using Xenon-SPECT and O 15-PET.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Cocaine Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Brain Imaging: Cocaine Effects & Medication Development

Resource links provided by NLM:


Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • Absolute change in rCBF at 5 & 15 minutes (Xe)
  • Relative change in rCBF at 5, 19, & 33 minutes (O15)
  • Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables

Enrollment: 0
Actual Study Start Date: December 30, 1995
Study Completion Date: December 30, 1995
Primary Completion Date: December 30, 1995 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 48 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000270


Locations
United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Herbert Kleber, M.D. New York State Psychiatric Institute
  More Information

Publications:
ACNP Abstract, 1995. CPDD Abstract, 1996. Society for Nuclear Medicine, 1996. Society for Neuroscience, 1997.

Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00000270     History of Changes
Other Study ID Numbers: NIDA-09236-5
5P50DA009236-18 ( U.S. NIH Grant/Contract )
P50-09236-5
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: August 2, 2017
Last Verified: July 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by New York State Psychiatric Institute:
cocaine

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents